| Outcome | Total Comparisons | Total Studies | All Studies | Oxybutynin IR | Oxybutynin ER | Tolterodine IR | Tolterodine ER | Trospium | Darifenacin | Solifenacin | Fesoterodine |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RR (95% CI) | RR (95% CI)(Szonyi et al., 1995) | RR (95% CI)(Lackner et al., 2008) | RR (95% CI)(Malone-Lee et al., 2001) | RR (95% CI)(DuBeau et al., 2012; Wagg et al., 2014; Zinner et al., 2002) | RR (95% CI)(Sand et al., 2011) | RR (95% CI)(Chapple et al., 2007a; Foote et al., 2005) | RR (95% CI)(Wagg et al., 2006) | RR (95% CI)(Dubeau et al., 2014; DuBeau et al., 2012; Kraus et al., 2010b; Wagg et al., 2013) | |||
| Administrative Problems | 1 | 1 | 0.50 (0.03–7.93) | -- | -- | -- | -- | -- | 0.50 (0.03–7.93) | -- | -- |
| AEs | 13 | 12 | 1.41 (1.12–1.78) | -- | 2.78 (0.12–4.57) | 3.53 (0.47–26.56) | 1.02 (0.67–1.56) | 1.14 (0.28–4.57) | 0.78 (0.42–1.48) | 1.44 (0.89–2.33) | 1.96 (1.45–2.64) |
| Cognitive Function AEs | 2 | 2 | 0.62 (0.03–12.30) | -- | -- | -- | -- | -- | -- | -- | 0.62 (0.03–12.30) |
| Constipation | 7 | 6 | 1.26 (0.53–3.04) | -- | -- | -- | 0.52 (0.07–3.69) | 2.06 (0.09–49.66) | 1.28 (0.25–6.60) | -- | 1.73 (0.46–6.53) |
| Death | 6† (4) | 6† (4) | 0.76 (0.16–3.49) | 2.79 (0.12–65.66) | 0.31 (0.01–7.23) | -- | 0.35 (0.01–8.48) | -- | † | -- | 1.00 (0.06–15.97)† |
| Decline in Medical Condition | 1 | 1 | 0.31 (0.01–7.23) | -- | 0.31 (0.01–7.23) | -- | -- | -- | -- | -- | -- |
| Did Not Meet Entrance Criteria | 1 | 1 | 0.56 (0.25–1.25) | -- | -- | -- | -- | -- | -- | -- | 0.56 (0.25–1.25) |
| Dizziness | 1 | 1 | 0.23 (0.01–5.52) | -- | -- | -- | -- | 0.23 (0.01–5.52) | -- | -- | -- |
| Dry Mouth | 6 | 5 | 3.01 (1.18–7.68) | -- | -- | 0.64 (0.06–6.91) | 2.61 (0.31–22.25) | -- | 2.51 (0.12–51.90) | -- | 4.79 (1.16–19.74) |
| Dry Throat | 1 | 1 | 2.06 (0.09–49.66) | -- | -- | -- | -- | 2.06 (0.09–49.66) | -- | -- | -- |
| Fall | 1 | 1 | 2.79 (0.12–65.66) | 2.79 (0.12–65.66) | -- | -- | -- | -- | -- | -- | -- |
| Flatulence | 1 | 1 | 0.23 (0.01–5.52) | -- | -- | -- | -- | 0.23 (0.01–5.52) | -- | -- | -- |
| Headache | 2 | 1 | 2.57 (0.29–22.58) | -- | -- | -- | 1.57 (0.06–38.40) | -- | -- | -- | 3.93 (0.20–75.81) |
| Heartburn/GERD | 1 | 1 | 2.79 (0.31–25.12) | 2.79 (0.31–25.12) | -- | -- | -- | -- | -- | -- | -- |
| Lost to Follow-up | 4 | 4 | 2.15 (0.54–8.50) | -- | -- | -- | 1.04 (0.07–16.55) | 3.43 (0.17–70.17) | 3.51 (0.18–67.52) | -- | 2.00 (0.18–21.93) |
| Other | 3 | 3 | 0.94 (0.42–2.14) | -- | -- | -- | -- | 0.14 (0.01–2.81) | -- | -- | 1.10 (0.47–2.58) |
| Protocol Violation | 4 | 4 | 0.72 (0.32–1.62) | -- | -- | -- | 1.04 (0.26–4.11) | 0.23 (0.01–5.52) | 0.25 (0.02–2.73) | -- | 0.83 (0.26–2.70) |
| Renal Pain | 1 | 1 | 2.06 (0.09–49.66) | -- | -- | -- | -- | 2.06 (0.09–49.66) | -- | -- | -- |
| Serious AEs | 2 | 2 | 0.34 (0.06–1.97)* | -- | -- | -- | 0.13 (0.02–1.03) | -- | 0.75 (0.13–4.43) | -- | -- |
| Subject Non-Compliance | 2 | 2 | 1.06 (0.41–2.72) | 0.93 (0.34–2.52) | -- | -- | -- | 3.43 (0.17–70.17) | -- | -- | -- |
| Total Discontinuation | 8 | 8 | 1.07 (0.85–1.34)* | 1.49 (0.56–3.95) | -- | 1.36 (0.49–3.83) | 0.75 (0.44–1.28) | 0.94 (0.40–2.19) | 0.69 (0.37–1.26) | -- | 1.20 (0.87–1.66) |
| UnsatisfactoryTherapeutic Effect | 5 | 5 | 0.54 (0.20–1.43)* | -- | -- | -- | 0.26 (0.03–2.31) | -- | 0.10 (0.00–2.08) | -- | 0.73 (0.24–2.21) |
| Urinary Retention | 4 | 4 | 3.44 (0.86–13.84) | -- | 2.78 (0.12–65.08) | -- | -- | 2.06 (0.09–49.66) | -- | -- | 4.32 (0.73–25.48) |
| Vertigo | 1 | 1 | 0.31 (0.01–7.30) | 0.31 (0.01–7.30) | -- | -- | -- | -- | -- | -- | -- |
| Vision Blurred | 2† (0) | 1† (0) | -- | -- | -- | -- | † | -- | -- | -- | † |
| Withdrew Consent | 6 | 6 | 0.73 (0.45–1.17) | 0.93 (0.21–4.20) | -- | -- | 0.69 (0.20–2.43) | 0.68 (0.10–4.71) | 1.25 (0.25–6.36) | -- | 0.58 (0.22–1.50)* |
*
= I2 >25%;
†
=Adverse Event noted in Study but 0 count
AEs = Adverse Events; CI = confidence intervals; ER = extended release; GERD = Gastroesophageal Reflux Disorder; IR = immediate release; RR= rate ratio